Expertise in
12
conditions

Dr. Jennifer A. Woyach

Hematology
Select Specialty Hosp-Columbus
410 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
17 Years of Experience
Expertise in
12
conditions
Select Specialty Hosp-Columbus
410 W 10th Ave, 
Columbus, OH 

Overview

Jennifer Woyach is a Hematologist practicing medicine in Columbus, Ohio. She has been practicing medicine for over 17 years.

Dr. Woyach is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 231 peer reviewed articles and participating in 16 clinical trials. Dr. Woyach is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Select Specialty Hosp-Columbus
410 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia
An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia
Enrollment Status: Recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bendamustine, Ibrutinib, Rituximab
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Daratumumab, Ibrutinib
Study Phase: Phase 1
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Lenalidomide, Anti-CD19 Monoclonal Antibody
Study Phase: Phase 2
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug, Other
Study Drugs: Selinexor, Ibrutinib
Study Phase: Phase 1
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
View 9 Less Clinical Trials

231 Total Publications

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Journal: Blood cancer discovery
Published: May 18, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.8 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kami Maddocks is a Hematologist practicing medicine in Columbus, Ohio. Dr. Maddocks is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maddocks is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (3.0 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy. Dr. Cataland is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.8 miles away)
800-293-5066
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jonathan Brammer is a Hematologist practicing medicine in Columbus, Ohio. He has been practicing medicine for over 17 years. Dr. Brammer is highly rated in 28 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Brammer is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute

460 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marcos De Lima is a Hematologist practicing medicine in Columbus, Ohio. Dr. De Lima is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The Osuccc-James

460 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-3196
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Blachly is a Hematologist practicing medicine in Columbus, Ohio. Dr. Blachly is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Hairy Cell Leukemia (HCL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Blachly is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

The Arthur G. James Cancer Hospital And Richard J. Solove Research Institute

460 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Seema Bhat is a Hematologist practicing medicine in Columbus, Ohio. Dr. Bhat is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Hairy Cell Leukemia (HCL), Richter Syndrome, and Bone Marrow Aspiration. Dr. Bhat is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer A. Woyach

How do I make an appointment with Dr. Jennifer A. Woyach?

You can book an appointment with Dr. Jennifer A. Woyach by calling their office at 614-293-7677. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer A. Woyach a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer A. Woyach is classified as an Elite expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer A. Woyach specialize in?

While Dr. Jennifer A. Woyach is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jennifer A. Woyach participate in research or clinical trials?

Yes. Dr. Jennifer A. Woyach has published 231 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Jennifer A. Woyach's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer A. Woyach accept my insurance?

Dr. Jennifer A. Woyach accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-7677 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Woyach's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile